Dangerous short : It's cheaper for Novo Nordisk to buy Oramed at $150/ share
According to Seeking Alpha article dated Feb 6th , Novo Nordisk are spending $3.65b of their own money on R&D for oral insulin tablet. It would be cheaper for them to buy Oramed for $150/ share ( ten times the current mkt cap) ... and they would get a drug which is more advanced ( a year or two ahead of Novo's trials) ... they would also take out a potential competitor before it possibly teams up with big pharma. They would maintain their quasi-monopoly. Shorts are playing to make $15 downside... but could lose $150 upside. Only a madman would short this... foolish risk-reward.